NEOS Investment Management LLC Purchases 110,950 Shares of Pfizer Inc. $PFE

NEOS Investment Management LLC grew its position in Pfizer Inc. (NYSE:PFE) by 13.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 930,777 shares of the biopharmaceutical company’s stock after buying an additional 110,950 shares during the period. NEOS Investment Management LLC’s holdings in Pfizer were worth $22,413,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Godfrey Financial Associates Inc. acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new position in shares of Pfizer in the second quarter valued at approximately $26,000. Field & Main Bank bought a new stake in shares of Pfizer during the second quarter worth $27,000. HFM Investment Advisors LLC increased its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $28.42 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock’s 50-day simple moving average is $25.98 and its 200 day simple moving average is $26.34. The company has a market cap of $161.98 billion, a P/E ratio of 37.40, a P/E/G ratio of 1.93 and a beta of 0.34. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.21.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s dividend payout ratio is presently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups. The approval supports continued vaccine revenue and adds to the company’s recent positive news flow. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Pfizer launched the VESPER-JM Phase 3 study of berobenatide in Japan, strengthening its effort to compete in the obesity-drug market. Successful development could provide a meaningful long-term growth opportunity beginning later this decade. Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan
• Positive Sentiment: Pfizer’s broader pipeline remains focused on obesity and oncology, with berobenatide and next-generation cancer treatments viewed as potential growth drivers from 2028 onward. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
• Positive Sentiment: Pfizer licensed its early-stage CD228V antibody-drug conjugate to Medicus Pharma in a deal valued at up to $1 billion plus royalties. The agreement could generate milestone and royalty income while sharing development responsibilities. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Neutral Sentiment: Pfizer completed a Phase 1 migraine-tablet study and is conducting a Phase 3 trial of tilrekimig for eczema. These updates demonstrate pipeline activity, but they do not yet provide confirmed commercial revenue. Pfizer’s Tilrekimig Eczema Trial
• Negative Sentiment: After gaining roughly 25% over the past year and trading near recent highs, valuation-based upside appears more limited. Investors are also weighing Pfizer’s elevated dividend yield and management’s commitment to maintaining the payout against ongoing post-pandemic earnings pressure.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.